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ELSEVIER 
Xenogeneic Humoral Graft-Vs-Host Disease Following 
Hamster-to-Rat Bone Marrow Transplantation 
T. Miki, Y.-H. Lee, A Tandin, V. Subbotin, R. Kuddus, AS. Rao, J.J. Fung, T.E. Starzl, and L.A Valdivia 
BONE marrow transplantation (BMT) is an effective 
strategy to induce tolerance across xenogeneic barri-
ers.l This approach has been used in the hamster-to-rat 
BMT model.2 However, all animals suffered from graft-vs-
host disease (GVHD). Although xenogeneic GVHD has 
been observed in other studies, it is not yet well character-
ized.3 Because xenograft rejection is primarily mediated by 
humoral mechanisms, we tested the hypothesis that, unlike 
allogeneic GVHD in which cellular mechanisms predomi-
nate, xenogeneic GVHD could also be humorally mediated. 
MATERIALS AND METHODS 
LEW rats underwent splenectomy (Spx) on day -7 and total body 
irradiation (TBI) of 10 Gy 3 days before BMT. 300 x 106 
unfractionated hamster bone marrow cells were infused intrave-
nously (IV). Rat recipients were divided into three groups: short-
term (7 days) and long-term (30 days) treatment groups (groups I 
and II, respectively) received tacrolimus 1 mg/kg/d intramuscularly 
beginning 1 day before BMT. whereas the control group (group 
III) did not receive any immunosuppressive agents. All recipients 
were observed for clinical signs of GVHD. Chimerism was detected 
by two-color flow cytometry using an FITC-conjugated rat anti-
hamster lymphocyte antibody and a biotinylated hamster anti-rat 
lymphocyte antibody. Cytotoxicity of recipient's sera against rat 
and hamster cells was measured by complement-dependent cyto-
toxicity (CDC). 
Several samples were treated with dithiothreitol (DTT) to 
determine whcthcr IgM or IgG was responsible for the cytotoxicity. 
Histopathologic studies were done with H & E. Immunofluores-
cence staining was performed to detect hamster anti-rat Ig on 
several organs. 
RESULTS 
Hamster bone marrow cells engrafted only in 25% of rats in 
the control group; more than 90% did so in both short-term 
and long-term tacrolimus treatment groups. In group I, six 
of nine animals showed dermatitis and three rats died 
around day 28 post-BMT as a result of humoral injury to 
the liver. In group II, none of the animals developed 
dem1atitis. but they all developed fatal humoral liver injury. 
Overall survival for animals in group II was shorter than 
that in group I (a median of 30.3 vs 53.7. respectively; 
P = .073). 
Flow cytometric analysis of peripheral blood lymphocytes 
showed more than 80% in both group I (86.5 ::': 2.5%) and 
0041-1345/00/$-see front matter 
Pll S0041-1345(00)01105-2 
1036 
group II (88.7 ::': 3%) at 4 weeks post-BMT. Humoral injury 
was suspected because some rat liver samples had extensive 
infarction with focal hepatocyte necrosis in zones 1 and 2, in 
addition to infiltration by polymorphonuclear leukocytes. 
The central vein and pericentral hepatocytes (zone 3) were 
not compromised. There were no signs of obvious humoral 
injury in other organs. Immunofluorescence staining 
showed hamster anti-rat immunogloblin deposition on the 
rat portal vein and focal necrotic area. In no other organs 
was such extensive deposition of antibody found. CDC test 
using sera from naive rats and hamsters showed that 
xenoreactive natural antibodies (XNA) were present in 
both species against each other. Anti-hamster XNA disap-
peared in BMT recipients. However, cytotoxic antibody 
titers against rat lymphocytes were found in some of the rats 
suffering from humoral injury to the liver, which were 
sensitive to DTT treatment. 
DISCUSSION 
This is the first evidence of humoral GVHD in xenogeneic 
BMT. There are several reports of successful mixed lym-
phohematopoietic chimerism in rat-to-mouse! and pig-to-
mouse animal combinations, but there is no description of 
humoral GVHD. Mice are not as prone to mount a 
deleterious humoral response due to deficiencies in several 
proteins of the complement system.4 Our data suggest that 
humoral GVHD can occur in other species where comple-
ment is more efficient. namely, the rat. 
The addition of tacrolimus treatment markedly increased 
the engraftment rate. However, the outcome differed with 
different lengths of tacrolimus administration. Rats receiv-
ing a 1-week course of tacrolimus developed cellular 
GVHD, expressed with symptoms similar to those of allo-
geneic GVHD in the rat.s These symptoms were absent in 
rats that received a long-term course of tacrolimus treat-
ment. Interestingly, these rats had severe liver damage that 
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was humorally mediated. DTI assay data suggest that this 
humoral injury was mediated by hamster IgM. 
We conclude that xenogeneic GVHD in our model may 
have a dual presentation: classical cellular GVHD not 
distinct to the allogeneic BMT and humoral GVHD. Al-
though cellular GVHD is a generalized phenomenon, the 
liver is the target organ in humoral GVHD and the degree 
of injury is potentiated by T-cell suppression. These findings 
suggest that problems regarding humoral GVHD must be 
considered in xenogeneic BMT. 
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